in vivoin vivo zebrafish models and screening methods disclosed facilitate the study and discovery of therapeutic compounds to treat sodium channel-related cardiac diseases, e.g., by increasing sodium channel function at the membrane.
While primary lymphedema is rare, numerous cancer patients develop secondary lymphedema, or the retention of lymphatic fluid. Lymphedema is characterized by progressive, irreversible fibroadipose tissue deposition. Non-surgical approaches such as compression therapy are the most common strategies to address lymphedema but are inadequate in the long term. Surgical procedures can reconstitute lymphatic drainage, but this approach is not curative. A new approach is needed to mitigate fibroadipose tissue deposition in lymphedema.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
Pulmonary arterial hypertension (PAH) exhibits an obliterative vasculopathy where complex, integrated pathobiological signaling pathways drive vascular remodeling. In PAH, the arteriopathy includes numerous endophenotypes that occur to differing extents across patients. Variability in the proteomic and genetic profile is observed, causing phenotypic heterogeneity and inconsistent clinical responses to drug therapies. We have used network medicine to discover modifiable therapeutic targets in PAH by generating patient-specific protein-protein interaction (PPI) networks to unmask molecular interactions that identify and distinguish groups of individual patients with the same clinical phenotype. This allows personalized clinical phenotyping in PAH in those patient groups. The findings here also clarify the relationship between PAH genetic risk and pathobiology on an individual patient level, and inform treatment rationales and personalized drug selection using the PPI networks. Overall, findings from this project will advance precision medicine in PAH with direct relevance to the clinical management of patients.
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
Described herein are chimeric antigen receptors (CARs) comprising an extracellular domain comprising a portion of an anti-triggering receptor expressed on myeloid cells 2 (TREM2) scFv for targeting macrophages expressing TREM2. Methods for producing and utilizing cells comprising the CAR are further provided herein.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/62 - DNA sequences coding for fusion proteins
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention provides a method to identify and use compounds for the inhibition of abnormal or dysregulated hepatic glucose production that results in elevated blood glucose levels and associated metabolic disorders. The invention is based on the surprising discovery that the glucagon forms an obligate binding complex with aP2, which is necessary for activation of the glucagon G-coupled protein receptor.
Determining a patient-level clinical endpoint prediction based on analysis of a three-dimensional volumetric image is discussed. One example method includes generating a set of patches from a volumetric image of a tissue sample. The method also includes employing a pretrained feature encoder to extract a set of features from the set of patches. The method additionally includes generating a volume-level feature associated with the volumetric image via an aggregation based on the set of features. The method further includes generating a clinical endpoint prediction based on the volume-level feature.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
7.
METHOD OF DELIVERY OF FUSOGENIC ONCOLYTIC VIRUS AND THERAPEUTIC MOLECULES
Malignant tumors that are resistant to conventional therapies represent significant therapeutic challenges. An embodiment of the present invention provides a method for treating cancer comprising administering to a subject in need thereof a checkpoint inhibitor in combination with a new generation regulatable fusogenic oncolytic herpes simplex virus-1 that is more effective at selective killing target cells, such as tumor cells. In various embodiments presented herein, the methods described herein is suitable for treatment of solid tumors, as well as other cancers.
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
8.
COMPOSITIONS AND THERAPEUTIC METHODS OF MICRORNA GENE DELIVERY
Described herein are compositions and methods for treating a disease in a subject by administering delivery vectors that express artificial microRNAs, artificial microRNA clusters, and/or a combination of microRNA clusters and associated non-coding RNAs to the subject. Also described herein are methods for preparing artificial microRNAs and artificial microRNA clusters.
Chimeric small molecules comprising an immunogenic display moiety and methods of using the chimeric small molecules to label proteins with the immunogenic display moiety for MHC display on the surface of a cell or to label cell surface proteins with the immunogenic display moiety for display on the surface of a cell, thereby inducing an immune response.
C07K 14/74 - Major histocompatibility complex [MHC]
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/078 - Cells from blood or from the immune system
KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and/or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided herein are compositions and methods using a therapeutic agent targeting mTORCI and a therapeutic agent targeting MDK for treating a Tuberous Sclerosis Complex (TSC)-associated disease, e.g., Angiomyolipoma (AML) and lymphangioleiomyomatosis (LAM), or for treating sporadic LAM/AML. Also provided are methods of identifying subjects for treatment, e.g., with checkpoint inhibitors.
KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for activating immune cells, for the treatment of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
13.
COMPOSITIONS AND METHODS FOR MAINTAINING A CCL3/CCL4 AND CCR5 INTERACTION PROGRAM EXPRESSED DURING TUMOR PROGRESSION
Embodiments disclosed herein provide compositions for increasing CCL3 and/or CCL4 interactions with CCR5 and/or CCR1 to enhance an immune response. Applicants identified specific interactions between CD8+ T cells and inflammatory monocytes/macrophages that change during tumor progression from small to medium to large tumors. The ligands CCL3 and CCL4 are expressed in a specific subset of T cells (CD8+ PD-1+ TIM3+ T cells). The receptors CCR5 and CCR1 are expressed in inflammatory monocytes/macrophages. Modulation or maintenance of these interactions can allow enhanced immune responses for treating cancer, as well as for vaccination.
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
14.
SYSTEMS, DEVICES, AND METHODS FOR GENERATING MACHINE LEARNING MODELS AND USING THE MACHINE LEARNING MODELS FOR EARLY PREDICTION AND PREVENTION OF PREECLAMPSIA
Disclosed herein are methods and systems for determining risk of preeclampsia. The system can include (a) a computer comprising: (i) a processor; and (II) a memory, coupled to the processor, the memory storing a module comprising: (1) test data for a sample from a subject including values indicating a quantitative measure of one or more markers; (2) a classification rule which, based on values including the measurements, classifies the subject as being at risk of preeclampsia, wherein the classification rule is configured to have a sensitivity of at least 75%, at least 85% or at least 95%; and (3) computer executable instructions for implementing the classification rule on the test data.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
15.
COMPOSITIONS AND METHODS FOR TREATING CHRONIC ALLOGRAFT REJECTION
The invention features compositions and methods for treating transplant recipients (e.g., chronic allograft rejection) using a senolytic agent and an angiotensin II receptor antagonist or using a senolytic agent and senomorphic agent. The methods and compositions are useful in a variety of transplant settings including, without limitation, solid organ transplants including kidney, lung, heart, liver, intestine, or pancreas transplantation procedures and cellular transplants including but not limited to bone marrow transplants.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
16.
SHEAR-THINNING COMPOSITIONS AS AN INTRAVASCULAR EMBOLIC AGENT
This disclosure relates to methods of using shear-thinning compositions in the treatment of a vascular disorders, cancers, infections, abscesses, and fistulas. The disclosure also relates to shear-thinning compositions comprising silicate nanoparticles, gelatin or a derivative thereof, and a contrast agent. In some examples, the shear-thinning compositions comprise about 1.5% to about 10% by weight of silicate nanoparticles and about 0.5% to about 6.75% by weight of gelatin or a derivative thereof.
The present disclosure describes methods of treating a skin disorder in a subject in need thereof and methods of locally suppressing an immune response in a tissue of a subject in need thereof. The methods can include contacting a microneedle array comprising a plurality of microneedles with a skin surface of the subject, wherein the plurality of microneedles comprises: i) a degradable hyaluronic acid polymer comprising a disulfide bond, and ii) a therapeutic agent; and applying pressure on the microneedle array such that the plurality of microneedles penetrates the skin surface, thereby releasing the therapeutic agent beneath the skin surface while simultaneously capturing ISF for successive analysis.
The present disclosure provides include kits, compositions, and methods related to impaired respiratory health (e.g., diseases and conditions relating to lung injury). In particular, the present disclosure provides include kits, compositions, and methods for quantifying protein biomarkers associated with impaired respiratory health and assessing the risk of, monitoring, treating and/or preventing, interstitial lung diseases (ILDs).
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
19.
LIPID NANOPARTICLES FOR THE TREATMENT OF VASCULAR DISEASES
Described herein are lipid nanoparticle (LNP) formulations with demonstrated tropism towards smooth muscle cells. Also described herein are LNPs conjugated with peptides that can target tissue or cell surface receptors. The formulations of the disclosure include amounts of DOTAP, an ionizable lipid, amounts of a neutral lipid; amounts of cholesterol; and amounts of one or more PEG-lipids with preferential tropism towards vascular smooth muscle cells (vSMCs). Also described herein are peptides that target receptors highly expressed on the surface of vSMCs (IL-6R, CD63 and GAL-3) or that target proteins in the extracellular matrix adjacent to vSMCs (Col-IV) increasing the uptake into these cells.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
20.
LIPID NANOPARTICLES FOR THE TREATMENT OF VASCULAR DISEASES
Described herein are lipid nanoparticle (LNP) formulations with demonstrated tropism towards smooth muscle cells. Also described herein are LNPs conjugated with peptides that can target tissue or cell surface receptors. The formulations of the disclosure include amounts of DOTAP, an ionizable lipid, amounts of a neutral lipid; amounts of cholesterol; and amounts of one or more PEG-lipids with preferential tropism towards vascular smooth muscle cells (vSMCs). Also described herein are peptides that target receptors highly expressed on the surface of vSMCs (1L-6R, CD63 and GAL-3) or that target proteins in the extracellular matrix adjacent to vSMCs (Col-IV) increasing the uptake into these cells.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
21.
ENPP1 GENE THERAPY FOR THE TREATMENT OF VASCULAR DISEASE
Provided herein are compositions and methods for gene therapy for disorders of arterial calcification as well as Generalized Arterial Calcification of Infancy (GACI). The methods include a gene addition strategy to deliver a DNA construct to target tissues (such as liver and smooth muscle cells) to express soluble recombinant ENPP1 (srENPP1) or transmembrane full-length recombinant ENPP1 (rENPP1).
Provided herein are compositions and methods for gene therapy for disorders of arterial calcification as well as Generalized Arterial Calcification of Infancy (GACI). The methods include a gene addition strategy to deliver a DNA construct to target tissues (such as liver and smooth muscle cells) to express soluble recombinant ENPP1 (srENPP1) or transmembrane full-length recombinant ENPP1 (rENPP1).
C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Featured are methods of identifying (e.g., diagnosing) and/or treating a subject having or at risk of developing a liver disorder, such as liver steatosis, liver fibrosis, liver cirrhosis, and/or liver cancer (e.g., HCC). The methods utilize predictive and/or diagnostic biomarkers for identifying a subject as having or having a risk of a liver disorder. The predictive and/or diagnostic biomarkers described herein can also be used to monitor the status of a subject determined to have liver disorder or a risk thereof during treatment with a liver therapy. Also disclosed are methods of treating a subject determined to have a liver disorder (e.g., liver cancer, such as HCC) or a risk thereof (e.g., by assessing the level of one or more of the disclosed biomarkers by administering a liver therapy to the subject.
Methods for single-cell sequencing of mitochondrial RNA are described. In some embodiments, the methods further involve the identification of malignant cells and/or characterization of tumor subclones in a biological sample.
The present disclosure describes a method of preparing a bioadhesive, pectin- based polymer film. The method includes mixing high-methoxyl pectin (HMP) and water to form an HMP putty ball; hydrating a surface of the HMP putty ball; pressing the HMP putty ball into an HMP film of a substantially uniform thickness; re- hydrating the HMP film; and de-watering the re-hydrated HMP film to a point of at least partial gel-to-glass phase transition. Methods of treating a wound of a subject in need thereof using the bioadhesive, pectin-based polymer film are also described.
The disclosure provides improved methods and devices to create a hammock effect to stabilize the urethra without creating an incision in the abdomen or the vagina, and without using a surgical mesh. Such implementations can also leave no permanent material in the body. The simplicity afforded by such procedures and methods permits treatment of patients on an outpatient basis, and avoids risks and disadvantages associated with the installation of a permanent mesh.
A61B 17/42 - Gynaecological or obstetrical instruments or methods
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
27.
COMPOSITIONS AND METHODS TARGETING SAT1 FOR ENHANCING ANTI-TUMOR IMMUNITY DURING TUMOR PROGRESSION
YEDA RESEARCH & DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE (Israel)
Inventor
Kuchroo, Vijay K.
Purohit, Vinee
Yosef, Nir
Wagner, Allon
Anderson, Ana Carrizosa
Mangani, Davide
Abstract
Embodiments disclosed herein provide compositions for enhancing anti-tumor immunity for treating cancer by targeting the polyamine pathway, and in particular inhibiting the function of the polyamine catabolic enzyme Sat1. In embodiments, Sat1 inhibition is targeted to CD4+ T cells, in particular Tregs.
Provided herein are compositions comprising Escherichia coli (E. coli), Saccharomyces boulardii (S. boulardii), Lactobacillus plantarum (L. plantarum), and/or Ensifer meliloti (E. meliloti) and a first stabilizing excipient. Also provided herein are methods of delivering E. coli, S. boulardii, L. plantarum, and/or E. meliloti to a subject in need thereof, methods of inducing bacterial growth in a subject or in a cell, tissue, or biological sample, and methods of inhibiting an enteric pathogen in a subject or in a cell, tissue, or biological sample. Further provided herein are methods of treating dysbiosis in a subject in need thereof.
Disclosed are compositions, kits, systems, and methods for treating or healing a wound. The compositions can include a carrier composition with a gas-entrapping material and a gas entrapped within the carrier composition.
A61K 33/00 - Medicinal preparations containing inorganic active ingredients
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
This disclosure provides novel integrases for site-specific genetic engineering. Also provided are systems, methods, and compositions for site-specific genetic engineering using Programmable Addition via Site-Specific Targeting Elements (PASTE) with the novel integrases.
Compositions for local delivery of a drug to an intracranial region, such as brain tissue or a brain tumor. Methods for locally delivering drug or therapy to an intracranial region. Compositions may include a hydrogel in which a chemotherapy drug or immunotherapy drug is dispersed. Kits that include compositions or solutions that may be combined to form compositions.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Featured are methods of treating an inflammatory condition or disorder in a subject in need thereof. The methods involve administering to the subject a therapeutically effective amount of an agent that reduces expression of or inhibits an activity of Granzyme K (GZMK).
A61K 38/57 - Protease inhibitors from animalsProtease inhibitors from humans
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
Described herein are methods and compositions that can be used to treat subjects with cancer by administering combinations of antibodies that target TIGIT and antibodies that target Jag1.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
THE BRIGHAM AND WOMEN'S HOSPITAL INCORPORATED (USA)
Inventor
Athanasiou, Lampros
King, Franklin
Hata, Nobuhiko
Kobayashi, Satoshi
Masaki, Fumitaro
Wollin, Daniel Arthur
Abstract
Disclosed are a device and a method of autonomous stone ablation during laser lithotripsy, the method including inserting a catheter into a lumen; navigating the catheter through the lumen along an insertion trajectory; obtaining at least one image of an object within the lumen; segmenting the at least one image; determining a size of the object; and in response to the size exceeding or being equal to a predetermined size: defining a region of lasing of the object, aligning a tip of the catheter with the region of lasing, and performing lithotripsy.
A61B 18/24 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibreHand-pieces therefor with a catheter
A61B 18/26 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibreHand-pieces therefor for producing a shock wave, e.g. laser lithotripsy
A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
The present disclosure relates to chimeric small molecules, which find utility as modifiers of target substrates according to the formula A-L1-E-B or A-L1-E-L2-B, wherein A is a kinase binding moiety; B is a target binding moiety; L1 and L2 are each a linker; and E is an electrophilic reactive group. Molecules according to the present invention find use making substrate modifications such as post-translational modifications to targets that are not the natural substrate of the kinase; accordingly, diseases or disorders may be treated or prevented with molecules of the present disclosure.
THE BRIGHAM AND WOMEN'S HOSPITAL INCORPORATED (USA)
Inventor
Masaki, Fumitaro
Kato, Takahisa
Hata, Nobuhiko
Kobayashi, Satoshi
King, Franklin
Ninni, Brian
Wollin, Daniel Arthur
Kibel, Adam Stuart
Abstract
The present disclosure relates to an apparatus and method for steering a continuum robot through an anatomy, including receiving an identification of a first target location; inserting the continuum robot into the anatomy; steering, during a first navigation, the continuum robot along a first path toward the first target location; storing, in a memory, location data of a plurality of points along the first path; receiving a selection of at least two points of the plurality of points; editing location data of the selected at least two points; and steering, during a second navigation, the continuum robot along a second path toward a second target location, with the second path differing from the first path based on the edit of the location data of the selected at least two points.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
THE BRIGHAM AND WOMEN'S HOSPITAL INCORPORATED (USA)
Inventor
Masaki, Fumitaro
Kato, Takahisa
Ninni, Brian
Hata, Nobuhiko
King, Franklin
Abstract
Examples of autonomous navigation, movement detection, and/or control include, but are not limited to, autonomous navigation of one or more portions of a continuum robot towards a particular target, movement detection of the continuum robot, Follow-The-Leader smoothing, and/or state change(s) for a continuum robot. Examples of applications include imaging, evaluating, and diagnosing biological objects, such as, but not limited to, for Gastro-intestinal, cardio, bronchial, and/or ophthalmic applications, and being obtained via one or more optical instruments, such as, but not limited to, optical probes, catheters, endoscopes, and bronchoscopes. Techniques provided herein also improve processing and imaging efficiency while achieving images that are more precise, and also achieve devices, systems, methods, and storage mediums that reduce mental and physical burden and improve ease of use.
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
Disclosed are compositions including a pharmaceutical agent assembled with a lipid composition, wherein the lipid composition comprises a lipidoid having structural Formula (I):
Disclosed are compositions including a pharmaceutical agent assembled with a lipid composition, wherein the lipid composition comprises a lipidoid having structural Formula (I):
Disclosed are compositions including a pharmaceutical agent assembled with a lipid composition, wherein the lipid composition comprises a lipidoid having structural Formula (I):
or a pharmaceutically acceptable salt thereof, wherein Ra, Rb1, Rb2, Rb3, Rb4, n1 and n2 are as described herein.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
39.
COMBINATION THERAPY WITH VENETOCLAX AND ZOTATIFIN FOR THE TREATMENT OF CANCER
The invention features methods of treating a subject having a cancer (e.g., leukemia (e.g., acute myeloid leukemia), solid tumor, breast cancer, lung cancer, colorectal cancer, or pancreatic cancer) by administering venetoclax or a pharmaceutically acceptable salt thereof in combination with zotatifin or a pharmaceutically acceptable salt thereof.
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61P 35/02 - Antineoplastic agents specific for leukemia
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
40.
AUTOANTIBODY BIOMARKERS FOR THE EARLY DETECTION OF OVARIAN CANCER
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
Inventor
Katchman, Benjamin
Anderson, Karen
Wallstrom, Garrick
Labaer, Joshua
Cramer, Daniel
Abstract
Compositions and methods relating to a panel of antigen biomarkers for the early detection of ovarian cancer. The compositions and methods encompass antigen biomarkers coupled to a substrate, with the biomarkers being selected from the group consisting of one or more of ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3.
KLRB1 binding agents (in particular anti-KLRB1 antibodies and antigen binding portion thereof) and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, INKT, peTh2, ILC2, ILC3, NK cells, and/or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
42.
IMIDAZO-PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGIC DISORDERS
The present disclosure relates to compounds of Formula (I): (I), or a pharmaceutically acceptable salt thereof, wherein: Ring A is or, and to their pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting EphB3 and may be used in the treatment of disorders in which EphB3 activity is implicated, such as neurodegenerative diseases and cancers.
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
As demonstrated herein, soluble human FcRn binds to AFP with affinities greater than observed with albumin, and is able to interfere with FcRn-mediated protection of and functional associations with IgG. Accordingly, provided herein, in some aspects, are compositions and methods to inhibit FcRn and AFP interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate FcRn and AFP interactions in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels increasing with immunosuppression.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
A glucose sensor is configured to be wrapped around a surface of an injection needle or cannula. The glucose sensor measures a glucose concentration of a patient when the injection needle or cannula is inserted into the patient. The glucose sensor includes a flexible substrate, at least two electrodes disposed on a surface of the flexible substrate, a glucose-responsive hydrogel at least partially disposed on a first electrode of the at least two electrodes, and a membrane permeable to glucose. The membrane is disposed on the glucose-responsive hydrogel. The total thickness of the glucose sensor is less than 10 pm.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
45.
SYSTEMS AND METHODS FOR TRANSCLIVAL TUMOR-TREATING FIELDS
An implantable device comprises a first support plate; a plurality of electrodes disposed on an outer surface of the first support plate, and a second support plate configured to be removably attached to the first support plate, wherein the electrodes are configured to generate a tumor treating field within a body surface.
The present disclosure relates to compounds of Formula (I): (I), and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting EphB3 and may be used in the treatment of disorders in which EphB3 activity is implicated, such as neurodegenerative diseases and cancers.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
47.
BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF
The present disclosure relates to chimeric small molecules, which find utility as modifiers of target substrates according to the formula A-L1-E-B or A-L1-E-L2-B, wherein A is a kinase binding moiety; B is a target binding moiety; L1 and L2 are each a linker; and E is an electrophilic reactive group. Molecules according to the present invention find use making substrate modifications such as post-translational modifications to targets that are not the natural substrate of the kinase; accordingly, diseases or disorders may be treated or prevented with molecules of the present disclosure.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
48.
COMPOSITIONS AND METHODS FOR REGULATING CARDIAC ANGIOGENESIS POST ISCHEMIA
Described herein are compositions (e.g., an inhibitory nucleic acid molecule) for reducing expression of decorin (DCN) and methods thereof for (i) treating a medical condition resulting from a myocardial infarction (Ml), and/or (ii) promoting angiogenesis in a subject. The inhibitory nucleic acid molecule may be a small interfering RNA (siRNA), a double-stranded RNA (dsRNA), an anti-sense oligonucleotide (ASO), a microRNA (miRNA), or a short hairpin RNA (shRNA)), or a gapmeR described herein, or a composition (e.g., pharmaceutical composition) thereof. Advantageously, the composition described herein provides therapeutic effects (e.g., angiogenesis) for cardiac tissue following myocardial infarction (Ml).
Described herein are compositions (e.g., an inhibitory nucleic acid molecule) for reducing expression of small EDRK-rich factor 2 (SERF2) and methods thereof for (i) treating cardiovascular disease (e.g., PAD, CAD, heart failure, cardiomyopathy, or stroke) in a subject; (ii) treating or reducing the likelihood of CTLI in a subject; (iii) alleviating chronic ischemic rest pain in a subject having CTLI; and/or (iv) promoting angiogenesis in a subject (e.g., a subject having or at risk of developing a cardiovascular disease). The inhibitory nucleic acid molecule may be a small interfering RNA (siRNA), a double-stranded RNA (dsRNA), an anti-sense oligonucleotide (ASO), a microRNA (miRNA), a short hairpin RNA (shRNA), or a gapmeR described herein, or a composition (e.g., pharmaceutical composition) thereof.
Disclosed herein are inhibitory nucleic acid molecules (e.g., a small interfering RNA (siRNA), a double-stranded RNA (dsRNA), an anti-sense oligonucleotide (ASO), a microRNA (miRNA), or a short hairpin RNA (shRNA)), or a gapmeR) for reducing expression of the long noncoding RNA (IncRNA) epigenetically induced MYC interacting IncRNA1 (EPIC1). Also disclosed herein are methods for treating arteriosclerosis (e.g., atherosclerosis, e.g., diabetes-associated atherosclerosis) in a subject using the EPIC1 inhibitory nucleic acid molecules.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE (Australia)
Inventor
Yeo, Boon Thye Thomas
Kong, Ru
Asplund, Christopher Lee
Xue, Aihuiping
Tor, Phern Chern
Tan, Xiaowei
Siddiqi, Shan H.
Fox, Michael D.
Cocchi, Luca
Burgher, Bjorn
Abstract
Disclosed is a method for determining a treatment to be applied to a brain of a patient, such as determining a transcranial magnetic stimulation (TMS) treatment location(s) and treatment strength to be applied to a brain of a patient suffering from depression. A search of the brain, based on coarse-scale parcellations, treatment metric and one or more anatomical metrics, is conducted to select the treatment location(s). In one embodiment, this involves progressively varying a value of a parameter associated with a gyrus threshold and for each value, identifying candidate treatment locations based on a functional connectivity of a subgenual anterior cingulate cortex during resting-state functional magnetic resonance imaging (fMRI) recorded over a plurality of multimodal brain imaging sessions, and selecting as the respective treatment location the candidate location that is closest to all other candidate treatment locations.
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
A61N 2/04 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets using variable fields, e.g. low frequency or pulsating fields
53.
APPARATUS AND METHOD FOR MULTIMODAL DATA FUSION FOR ACCURATE DIAGNOSIS
According to some embodiments, a method comprises obtaining data in multiple modalities, including data in an image modality and data in a biomarker modality; obtaining one or more trained machine-learning models; generating a first multi-modality group from the data in multiple modalities, wherein the first multi-modality group includes data in at least the image modality and in the biomarker modality; generating a group of intermediate data, wherein generating the group of intermediate data includes inputting the first multi-modality group into a machine-learning model that has been trained to extract features from input multi-modality data and output the features as the intermediate data; and generating a first classification result based on at least the group of intermediate data, wherein generating the first classification result includes inputting the intermediate data into a machine-learning model that has been trained to output the classification result based on the group of intermediate data.
Some aspects of the present disclosure are generally related to injectable compositions, for example, for intratumoral drug delivery. In some embodiments, the injectable composition comprises a polymer configured to undergo a solution-gel transition when heated from room temperature to at or around body temperature, allowing for the injection of the injectable composition as a liquid with subsequent gelation to retain the composition at the injection location. In some embodiments, the injectable compositions may be capable of encapsulating radio-opaque label and/or a hydrophobic immunoadjuvant (e.g., imiquimod) at a concentration of greater than or equal to 0.5 mg/mL. Accordingly, some aspects of the present disclosure are related to the radio-opaque label facilitating visualization of the injectable composition during injection and/or the retention of the injectable composition at the injection location, allowing for localized and extended-release of the immunoadjuvant. Still other aspects are generally directed to related methods, kits, or the like.
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 18/02 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES (France)
Inventor
Djeffal-Vincentelli, Yannis
Pourquie, Olivier
Abstract
A composition of INFRA cells is described. The composition includes human muscle stem cells (SCs) expressing the transcription factor PAX7 and lacking the expression of the transmembrane receptor PDGFRA, wherein at least 70% of the population of human muscle SCs are PAX7+ and PDGFRA-. Methods of preparing the INFRA cell compositions, and methods of using the INFRA cells to treat muscle injury are also described.
ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES (France)
Inventor
Djeffal-Vincentelli, Yannis
Pourquie, Olivier
Rodriguez De La Rosa, Alejandra
Abstract
Systems and methods are provided for generating a cell differentation protocol for a target cell type. A low-dimensional graph is generated from a genomics dataset representing a target cell type. The low-dimensional graph is analyzed to determine a set of trajectories within the low-dimensional graph. A score is assigned to each of the set of trajectories based on gene expression associated with the target gene within the trajectory. A trajectory of the set of trajectories having a best score is selected.
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16B 99/00 - Subject matter not provided for in other groups of this subclass
57.
TREATMENT OF PERIVASCULAR FIBROSIS AND OTHER HYPERTENSIVE DISEASES AND CONDITIONS
The disclosure features methods and compositions for the treatment of perivascular fibrosis and other hypertensive diseases and conditions, cardiovascular diseases, and chronic kidney disease.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 9/00 - Drugs for disorders of the cardiovascular system
A drug delivery device for administration to a subject is provided. In some embodiments, the drug delivery device includes a reservoir containing an active pharmaceutical ingredient and a potential energy source. The drug delivery device also includes a trigger operatively associated with the potential energy source, where the trigger is configured to actuate at a predetermined location within the subject. The drug delivery device also includes a rupturable membrane disposed along a flow path extending between the reservoir and an outlet, where the membrane is configured to rupture when the trigger is actuated. Once the trigger is actuated, the potential energy from the potential energy source may be released to expel the active pharmaceutical ingredient in a jet through the outlet.
The present invention relates to a method of treating inflammation in a mammal in need thereof that involves providing a mammal with elevated host endogenous reverse transcriptase produced by host endogenous retroviruses (ERVs), and thereafter contacting in vivo the reverse transcriptase with a reverse transcriptase inhibitor in an amount sufficient to ameliorate ERV- induced inflammatory response.
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
60.
BI-SPECIFIC ANTIBODIES AGAINST TIM-3 AND PD-1 FOR IMMUNOTHERAPY IN CHRONIC IMMUNE CONDITIONS
Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
61.
VERO CELL LINES STABLY EXPRESSING HSV ICP0 PROTEIN
Provided herein are Vero cell lines that stably express Herpes Simplex Virus (HSV) ICP0 protein. These cells have the same morphology of Vero cells, exhibit stable expression of HSV ICP0 protein, and also efficiently complement replication of HSV ICP0 deficient virus for greater than 20, 30, or even 40 cell passages.
The application presently discloses a method of treating atherosclerosis in a human subject comprising administering an effective amount of an IL-8 inhibitor, an IL-6 inhibitor, and/or an IL-1β inhibitor, wherein the subject has a TET2 and/or DNMT3A mutation thereby treating atherosclerosis. It also discloses a method for treating atherosclerosis in a human subject comprising sequencing at least a part of a genome comprising TET2 and/or DNMT3A of one or more cells in a blood sample of the subject; determining from the sequencing whether the subject has one or more mutations in TET2 and/or DNMT3A, if it is determined that the subject has at least one TET2 and/or DNMT3A mutation, administering an IL-8 inhibitor, an IL-6 inhibitor, and/or an IL-1β inhibitor to a subject to the subject thereby treating atherosclerosis.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Engineered ionophores capable of increased metal ion transport across hydrophobic membranes and/or reduced metal ion binding affinity, pharmaceutical compositions thereof, kits thereof, ion-selective membrane devices thereof, and methods of use thereof. Hydrophobic membranes can be biological, e.g., cell membranes, or nonbiological, e.g., ion-selective membranes. Engineered ionophores can comprise a metal ion chelator group comprising: a polar binding site having binding atoms to form a metal ion chelate complex; and one or more shielding group(s) in proximity to the binding atoms. Shielding groups can increase the hydrophobic membrane permeability and reduce the binding affinity of the chelate complex. Methods of use can comprise contacting said membranes with said engineered ionophores, metal ion chelate complexes thereof, pharmaceutical compositions thereof, the components of kits thereof, or the like, or any combination thereof. Methods of treatment comprise administering the same to a human or non-human animal, plant, or part thereof, e.g. cells.
C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
The systems and methods described herein determine metrics of cardiac performance via a mechanical circulatory support device and use the cardiac performance to calibrate, control and deliver mechanical circulatory support for the heart. The systems include a controller configured to operate the device, receive inputs indicative of device operating conditions and hemodynamic parameters, and determine vascular performance, including vascular resistance and compliance, and native cardiac output. The systems and methods operate by using the mechanical circulatory support device (e.g., a heart pump) to introduce controlled perturbations of the vascular system and, in response, determine heart parameters such as stroke volume, vascular resistance and compliance, left ventricular end diastolic pressure, and ultimately determine native cardiac output.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
A61B 5/021 - Measuring pressure in heart or blood vessels
A61B 5/0215 - Measuring pressure in heart or blood vessels by means inserted into the body
A61M 60/13 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel by means of a catheter allowing explantation, e.g. catheter pumps temporarily introduced via the vascular system
A61M 60/135 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel inside a blood vessel, e.g. using grafting
A61M 60/148 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel in line with a blood vessel using resection or like techniques, e.g. permanent endovascular heart assist devices
A61M 60/216 - Non-positive displacement blood pumps including a rotating member acting on the blood, e.g. impeller
A61M 60/411 - Details relating to driving for non-positive displacement blood pumps the force acting on the blood contacting member being mechanical, e.g. transmitted by a shaft or cable generated by an electromotor
A61M 60/515 - Regulation using real-time patient data
A61M 60/523 - Regulation using real-time patient data using blood flow data, e.g. from blood flow transducers
A61M 60/531 - Regulation using real-time patient data using blood pressure data, e.g. from blood pressure sensors
A61M 60/538 - Regulation using real-time blood pump operational parameter data, e.g. motor current
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
65.
METHODS OF TREATING CARDIOVASCULAR DISEASE ASSOCIATED WITH CALCIFICATION
The invention features methods of treating cardiovascular disease associated with calcification (e.g., aortic stenosis, coronary atherosclerosis, PAD, vein graft failure, AV fistula failure, bicuspid aortic valves, myocardial calcification, pericardial calcification, portal vein calcification, calcific uremic arteriopathy, and Hutchinson-Gilford progeria syndrome) by administering to the subject pemafibrate or a pharmaceutically acceptable salt thereof.
Systems and methods are provided for analysis of pathology data. Either a input data representing a pathology or a search query is received as an input and a first set of tokens is generated from the one of the input data representing a pathology and the search query from the input. The first set of tokens is matched to a second set of tokens at a multimodal fusion model trained on a pretraining dataset complied from a plurality of pathology-related sources. An output is provided based on the second set of tokens.
G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
G06V 10/74 - Image or video pattern matchingProximity measures in feature spaces
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
G06V 10/80 - Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 70/60 - ICT specially adapted for the handling or processing of medical references relating to pathologies
67.
BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES
The present disclosure relates to bifunctional chemical conjugation molecules, which find utility as modifiers of target substrates. The present disclosure includes multifunctional compounds comprising an enzyme binding moiety, a chemical linker moiety, and a target binding moiety, which may further include an electrophilic reactive group. Molecules according to the present invention find use making substrate modifications such as post-translational modifications to proteins that are not the natural substrate of the enzyme. Diseases or disorders may be treated or prevented with molecules of the present disclosure.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
68.
COMBINATIONS OF FORALUMAB WITH GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AGONISTS OR SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS AND METHODS OF USE THEREOF
This disclosure relates to composition and methods for the treatment, prevention and reduction of a comorbidity associated with chronic inflammation such as obesity, Type 1 Diabetes (T1), Type 2 Diabetes (T2D), metabolic syndrome, chronic kidney disease, and cardiovascular risk, as well as methods for improving the efficacy of GLP-1 agonists.
The present disclosure provides, inter alia, anti-peripheral lymph node address in antibodies and antigen binding fragments thereof. The present disclosure also provides compositions comprising drug-containing polymeric particles that mimic lymphocyte migration in vivo and can specifically deliver immunosuppressive or immunoregulatory drugs to lymphoid tissues and sites of chronic inflammation where T-cell activation and T-cell mediated injury are occurring; such compositions comprise the antibodies or antigen-binding fragments thereof described in the disclosure. The present disclosure also comprises antibody-drug conjugates and compositions comprising the antibody-drug conjugates. Methods of preparing and using these antibodies, antigen-binding fragments thereof, and compositions thereof are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
70.
ELECTROPHILIC REACTIVE LINKERS FOR LABELING OF POLYPEPTIDES AND METHODS OF USE THEREOF
1112122 are linking molecules. Molecules according to the present invention find use, for example, in multifunctional chimeric molecules (e.g., bifunctional molecules), which make substrate modifications such as post-translational modifications to targets that are not the natural substrate; accordingly, diseases or disorders may be treated or prevented with molecules of the present disclosure.
Systems and methods are provided for providing natural language decision support for pathology. A lower-dimensionality representation of each of a set of received pathology image is generated and a first set of tokens is generated from the representations of the set of pathology images by projecting the lower-dimensionality representations of the received pathology images to a same dimension as an embedding space of a large language model for text tokens or through multimodal blocks added to the large language model such as cross-attention. The large language model is trained on an instruction dataset complied from a plurality of pathology-related sources. A second set of tokens associated with a natural language prompt is received at the large language model. A response is determined from the first set of tokens and the second set of tokens at the large language model.
G06F 16/40 - Information retrievalDatabase structures thereforFile system structures therefor of multimedia data, e.g. slideshows comprising image and additional audio data
G06F 16/483 - Retrieval characterised by using metadata, e.g. metadata not derived from the content or metadata generated manually using metadata automatically derived from the content
G06F 16/487 - Retrieval characterised by using metadata, e.g. metadata not derived from the content or metadata generated manually using geographical or spatial information, e.g. location
G06F 16/50 - Information retrievalDatabase structures thereforFile system structures therefor of still image data
G06F 16/532 - Query formulation, e.g. graphical querying
This disclosure relates to GABA-A receptor positive allosteric modulators such as compounds of Formula (I), and pharmaceutically acceptable salts thereof, which are useful in treating neurological disorders, such as essential tremor, epilepsy, and seizure.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
73.
SOLID ORAL DOSAGE FORMS, KITS, AND METHODS OF USING THE SAME
in vivo in situ in situ in a subject. In particular, the solid oral dosage forms, methods, and kits disclosed herein are particularly useful for drugs that require more than once daily administration (e.g, drugs that have short half-lives).
A61K 9/24 - Layered or laminated unitary dosage forms
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
An information processing apparatus according to an embodiment includes processing circuitry. The processing circuitry is configured to generate at least a part of a first inference model that, upon receipt of an input of at least one two-dimensional image included in a three-dimensional image, outputs a first inference result corresponding to the two-dimensional image and a second inference model that, upon receipt of an input of two or more of the first inference results, outputs a second inference result corresponding to the three-dimensional image.
G06N 3/043 - Architecture, e.g. interconnection topology based on fuzzy logic, fuzzy membership or fuzzy inference, e.g. adaptive neuro-fuzzy inference systems [ANFIS]
G06N 7/00 - Computing arrangements based on specific mathematical models
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
An improved patient monitoring system can include a processor device, a display, a first sensor in communication with the processor device, the first sensor being at least one of an electrocardiogram sensor, a pressure sensor, a blood oxygenation sensor, an image sensor, an impedance sensor, or a physiological sensor. The system can include a second sensor in communication with the processor device, the second sensor being a physiological sensor. The processor device can be configured to utilize the first accuracy, the second accuracy, the first correlation, the second correlation to determine a recommendation for fusing the first data model with the second data model.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
The disclosure includes zinc prodrugs for targeted delivery of therapeutic, diagnostic or imaging agents to β-cells and methods of use therefor. The disclosure also includes targeted delivery of small molecules to β-cells that stabilize and activate CRISPR effector proteins comprising at least one destabilization domain, to enable CRISPR-based genome editing and transcriptional activation or repression in β-cells.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Systems and methods are provided for providing natural language decision support for pathology. A lower-dimensionality representation of each of a set of received pathology image is generated and a first set of tokens is generated from the representations of the set of pathology images by projecting the lower-dimensionality representations of the received pathology images to a same dimension as an embedding space of a large language model for text tokens or through multimodal blocks added to the large language model such as cross-attention. The large language model is trained on an instruction dataset complied from a plurality of pathology-related sources. A second set of tokens associated with a natural language prompt is received at the large language model. A response is determined from the first set of tokens and the second set of tokens at the large language model.
G06F 40/284 - Lexical analysis, e.g. tokenisation or collocates
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Described herein are methods for treating fibrosis, e.g., kidney fibrosis, using agents that target Secreted Modular Calcium-binding protein 2 (SMOC2).
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
The present invention relates to novel biomarkers and combinations thereof for cell type-specific and/or organ-specific extracellular vesicles, in particular, brain-specific and/or neuron-specific extracellular vesicles. The present invention also provides methods for isolation and/or enrichment of cell type-specific and/or organ-specific extracellular vesicles, methods for identification of extracellular vesicles derived from a cell, and methods for diagnosing or prognosing a disorder, e.g., a neurodegenerative disorder, using the cell type specific and/or organ-specific extracellular vesicles. Compositions in the form of kits of reagents for detecting the cell type-specific and/or organ-specific extracellular vesicles are also provided.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Provided herein are methods and kits for the rapid testing of biomarkers in human skin that are upregulated within 24 hours, across a range of dosages, to identify patients who have been exposed to radiation.
G01N 33/567 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent utilising isolate of tissue or organ as binding agent
G01N 33/483 - Physical analysis of biological material
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (Republic of Korea)
Inventor
Lee, Yuhan
Karp, Jeffrey M.
Park, Seongiun
Nam, Kum Seok
Park, Geonhu
Kim, Yeji
Hwang, Kiwook
Abstract
A pressure-sensitive adhesive (PSA), method of manufacturing a PSA, and various uses thereof synergistically combines the advantages of viscoelastic PSAs and bioadhesives. Enabled by a one-pot scalable copolymerization of a polyester and hydrophilic polymer, the PSA provides near-instant (~ 1 s), robust, and repeatable (over 1,000 times) adhesion to wet biological tissues (i.e., skin, lung, heart) and engineering (i.e., metals, plastics) substrates without prior surface functionalization.
A61F 13/0246 - Adhesive bandages or dressings characterised by the skin-adhering layer
C09J 167/03 - Polyesters derived from dicarboxylic acids and dihydroxy compounds the dicarboxylic acids and dihydroxy compounds having the hydroxy and the carboxyl groups directly linked to aromatic rings
C09J 7/25 - PlasticsMetallised plastics based on macromolecular compounds obtained otherwise than by reactions involving only carbon-to-carbon unsaturated bonds
85.
METHODS FOR GENERATING FUNCTIONAL HEMATOPOIETIC STEM CELLS
Described in the present application are methods for preparing populations of hematopoietic stem cells (HSCs), e.g., autologous and/or allogenic HSCs, using mechanical stretching or Trpv4 agonists, and methods of use of the HSCs in transplantation. In some embodiments, the methods include providing a population comprising hemogenic endothelial (HE) cells, and (i) contacting the HE cells with an amount of an agonist of transient receptor potential cation channel-subfamily vanilloid member 4 (Trpv4); and/or (ii) subjecting the cells to cyclic 2-dimensional stretching, for a time and under conditions sufficient to stimulating endothelial-to-HSC transition. Also provided herein are methods for treating subjects who have, bone marrow, metabolic, and immune diseases; the methods include administering to the subject a therapeutically effective amount of hematopoietic stem cells (HSCs) obtained by a method described herein.
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
This disclosure relates to pectin-based polymer compositions and methods of use thereof to cover, protect, and seal injuries, e.g., surgical wounds, in a mesothelial tissue. The methods include obtaining a bioadhesive pectin-based polymer composition including a complex of high-methoxyl pectin (HMP) and carboxymethylcellulose (CMC) in a ratio from about 10 to 1 to 1 to 10 by weight; applying the composition to an injured mesothelial tissue; and applying pressure for at least one minute to enable the composition to bind to the mesothelial tissue.
The disclosure provides compositions and methods for identifying subjects having hepatocyte stress associated with a risk for developing hepatocellular carcinoma (HCC), and therapeutic methods for reducing a subject's risk of HCC, for example, by inhibiting RELB, SOX4, or HMGCS2.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
89.
SYSTEMS AND METHODS FOR EVALUATION OF CIRCADIAN RHYTHM AND SLEEP HOMEOSTASIS
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
Inventor
Mignot, Emmanuel
Specht, Adrien
Duffy, Jeanne F.
Abstract
Systems and methods for assessment of circadian rhythm and sleep homeostasis are described. Presence of proteinaceous biomarkers within an individual's biological sample can be utilized in a computational classifier to indicate rhythmic phase and/or sleep homeostasis. Further clinical analysis and/or treatments can be performed based on determined rhythmic phase or sleep homeostasis.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
90.
MOUNTING DEVICE OF A STEREOTACTIC SYSTEM AND METHOD OF USE THEREOF
A stereotactic system for attachment to a skull of a patient can include a mounting device that can include a mounting base configured to be attached to the skull, a sheath removably attached to the mounting base, a guide frame, and a guide member. The guide frame has a frame body that removably attaches to the mounting base and receives the sheath, a plurality of arms extending outwardly from the frame body, and a plurality of fiducials attached to the plurality of arms. The guide member is received within the frame body and receives the sheath such that the sheath is pivotable relative to the mounting base within the guide member. The guide member is configured to fixedly secure the sheath to the mounting base.
A61B 90/11 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis with guides for needles or instruments, e.g. arcuate slides or ball joints
A61B 1/317 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for introducing through surgical openings, e.g. laparoscopes for bones or joints, e.g. osteoscopes, arthroscopes
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 90/10 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis
91.
SYSTEM AND METHOD FOR PROTEIN CORONA SENSOR ARRAY FOR EARLY DETECTION OF DISEASES
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Provided herein are methods and compositions for determining if a subject diagnosed with a CEACAM1-related disease or disorder is administered a CEACAM1 antibody or antigen-binding agent as a treatment.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
93.
TREATMENT OF SOLID TUMORS WITH IMPLANTABLE POLYMERS WITH SMALL MOLECULES OR CELLS
Disclosed are implantable polymers that release therapeutic agents in proximity to a tumor in a patient. In some embodiments, a polyethylene glycol hydrogel can release a STING agonist and/or a CAR-T cell in proximity to a phosphatase and tensin homolog (PTEN)-null triple negative breast cancer (TNBC) in the patient.
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 9/52 - Sustained or differential release type
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
Disclosed are implantable polymers that release therapeutic agents in proximity to a tumor in a patient. In some embodiments, a polyethylene glycol hydrogel can release a small molecule, like a STING agonist in proximity to a phosphatase and tensin homolog (PTEN)-null triple negative breast cancer (TNBC) in the patient.
THE BRIGHAM AND WOMEN'S HOSPITAL INCORPORATED (USA)
Inventor
Masaki, Fumitaro
Ninni, Brian
King, Franklin
Hata, Nobuhiko
Abstract
A system for, display controller connected to, and a method of, operating a robotic catheter system which is configured to manipulate a catheter having one or more bending segments along the catheter's length and a catheter tip at the distal end thereof, and which includes an actuator unit coupled to the bending segments via one or more drive wires arranged along a wall of the catheter. The method comprising: inserting at least part of the catheter into a lumen along an insertion trajectory that spans from an insertion point to a target; causing the actuator unit to actuate at least one of the one or more drive wires to align the catheter tip with the target; determining the position and/or orientation of the catheter tip with respect to the target; and displaying information about an accuracy of alignment between the catheter tip with respect to the target.
A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
96.
DETERMINING WHETHER AN IBD PATIENT WILL RESPOND TO 5-ASA THERAPY
The invention relates to a method of determining whether a patient diagnosed with inflammatory bowel disease (will respond to 5-ASA therapy which includes the steps of: obtaining a stool sample from the patient, analyzing the sample for the presence of microbial acetyltransferase genes capable of converting 5-ASA to the clinically ineffective N-acetyl 5-ASA, if microbial acetyltransferase genes are not present in the sample, the patient will respond to 5-ASA therapy and such therapy should be administered; if microbial acetyltransferase genes are present in the sample, the patient will not respond to 5-ASA therapy and a second line therapy should be administered.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/606 - Salicylic acidDerivatives thereof having amino groups
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
97.
METHODS OF PREDICTING RELAPSE POST HEMATOPOIETIC STEM-CELL TRANSPLANTATION AND METHODS OF TREATMENT
Methods of predicting relapse in a patient post HSCT, and methods of treatment, the methods including obtaining a bone marrow sample from the patient post- transplantation; and determining TCR clonal diversity of a population of T cells within the bone marrow sample; wherein TCR clonal diversity is indicative of risk of relapse.
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Described herein are termination-readthrough-based gene switches that are small (only 9 nucleotides) and do not introduce any foreign protein into the target cell, and that can be used to alter expression levels of transgenes in a cell.
A therapeutic or diagnostic delivery system, and methods of making and using the same, are disclosed. The system is a solvent free, injectable, biodegradable, and in situ crosslinking depot (ISCD) platform for ultra-long-term release of hydrophilic drugs.
A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 9/00 - Medicinal preparations characterised by special physical form
The present disclosure related to methods of treating various diseases that can benefit from modulating angiogenesis and/or endothelial-to-mesenchymal transition (EndMT) pathways, such as retinopathies and cancer, by modulating family with sequence similarity 222 member A (FAM222A) expression in the endothelium (e.g., endothelial cells) of a subject. For example, FAM222A can be modulated with FAM222A inhibitors described herein, thereby reducing angiogenesis, or FAM222A activators described herein, thereby increasing angiogenesis.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
